Before revision: Eftilagimod alpha URL development code IMP321 or efti) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep.
After revision: Eftilagimod alpha (INN; development code IMP321 or efti) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep.